Zoetis (ZTS) Income from Continuing Operations (2012 - 2026)

Zoetis' (ZTS) quarterly Income from Continuing Operations came in at 601000000.0 in Q1 2026, little changed year-on-year from 602000000.0 in Q1 2025, and little changed on a QoQ basis from 603000000.0 in Q4 2025.

Zoetis (ZTS) Income from Continuing Operations (2012 - 2026) Analysis & Trends

Zoetis (ZTS) has 15 years of Income from Continuing Operations data on file, last reported at 601000000.0 in Q1 2026.

  • On a quarterly basis, Income from Continuing Operations changed 0.17% year-over-year to 601000000.0 in Q1 2026; TTM through Mar 2026 was 2643000000.0, a 5.76% increase from a year earlier, with the FY2025 full-year figure at 2673000000.0, up 7.09% from the prior year.
  • Income from Continuing Operations for Q1 2026 stood at 601000000.0, roughly flat from 603000000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for ZTS reached as high as 721000000.0 in Q3 2025 and fell as low as 460000000.0 in Q4 2022.
  • Historically, Income from Continuing Operations has averaged 599529411.76 across 5 years, with a median of 599000000.0 in 2024.
  • On a YoY basis, Income from Continuing Operations climbed as much as 26.65% in 2023 and fell as far as 7.24% in 2023.
  • Year by year, Income from Continuing Operations stood at 460000000.0 in 2022, then grew by 13.7% to 523000000.0 in 2023, then gained by 11.09% to 581000000.0 in 2024, then grew by 3.79% to 603000000.0 in 2025, then retreated by 0.33% to 601000000.0 in 2026.
  • Per Business Quant data, the three most recent Income from Continuing Operations figures were 601000000.0 in Q1 2026, 603000000.0 in Q4 2025, and 721000000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Haleon 88.07 Bn 86.20 Bn - -
2 Teva Pharmaceutical Industries 35.75 Bn 32.01 Bn 1.97 Bn 370.00 Mn
3 Zoetis 31.84 Bn 29.90 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 27.18 Bn 23.12 Bn 4.39 Bn -3.58 Bn
5 United Therapeutics 23.09 Bn 20.93 Bn 648.10 Mn 274.90 Mn
6 RedHill Biopharma 21.32 Bn 21.32 Bn - -
7 Viatris 19.96 Bn 18.16 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.66 Bn 16.34 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.44 Bn 12.02 Bn 785.00 Mn 57.00 Mn
10 Vireo Growth 10.53 Bn 10.38 Bn 59.30 Mn -22.50 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 601.00 Mn
Dec 31, 2025 603.00 Mn
Sep 30, 2025 721.00 Mn
Jun 30, 2025 718.00 Mn
Mar 31, 2025 602.00 Mn
Dec 31, 2024 581.00 Mn
Sep 30, 2024 692.00 Mn
Jun 30, 2024 624.00 Mn
Mar 31, 2024 599.00 Mn
Dec 31, 2023 523.00 Mn
Sep 30, 2023 596.00 Mn
Jun 30, 2023 670.00 Mn
Mar 31, 2023 551.00 Mn
Dec 31, 2022 460.00 Mn
Sep 30, 2022 528.00 Mn
Jun 30, 2022 529.00 Mn
Mar 31, 2022 594.00 Mn
Dec 31, 2021 413.00 Mn
Sep 30, 2021 552.00 Mn
Jun 30, 2021 511.00 Mn